SELLAS Life Sciences Group, Inc.
(NASDAQ : SLS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.90%194.181.2%$592.16m
GILDGilead Sciences, Inc.
-0.83%69.200.9%$496.51m
BIIBBiogen Inc.
0.72%324.051.3%$476.94m
CELGCelgene Corporation
-0.47%69.651.2%$474.00m
ILMNIllumina, Inc.
0.13%319.933.5%$402.89m
REGNRegeneron Pharmaceuticals, Inc.
1.08%345.332.6%$297.08m
VRTXVertex Pharmaceuticals Incorporated
-0.94%165.111.9%$277.86m
ALXNAlexion Pharmaceuticals, Inc.
-0.89%118.622.0%$201.35m
AAgilent Technologies, Inc.
0.42%64.991.5%$188.27m
EXASExact Sciences Corporation
3.65%71.3825.3%$147.45m
SRPTSarepta Therapeutics, Inc.
0.07%119.0415.4%$145.09m
LGNDLigand Pharmaceuticals Incorporated
1.68%154.4623.3%$145.09m
ECYTEndocyte, Inc.
0.25%23.672.0%$124.13m
INCYIncyte Corporation
2.28%66.512.5%$117.76m
NKTRNektar Therapeutics
0.11%38.235.6%$117.70m

Company Profile

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. The company was founded on April 3, 2006 and is headquartered in New York, NY.